This message was sent to ##Email##
|
|
|
|
|
| |
| HEALTH CARE NEWS AND UPDATES |
The JAMA Network
Breast implants are among the most commonly used medical devices. Since 2008, the number of women with breast implants diagnosed with anaplastic large-cell lymphoma in the breast (breast-ALCL) has increased, and several reports have suggested an association between breast implants and risk of breast-ALCL. However, relative and absolute risks of breast-ALCL in women with implants are still unknown, precluding evidence-based counseling about implants.
READ MORE
World Cancer Day
With only one month to go until World Cancer Day, here are some top things to know to help make your voice heard this coming Feb. 4. Spread the message on social media this World Cancer Day and show the world the great actions you’re taking to help fight cancer.
READ MORE
The Medical News
A research team led by National University Health System (NUHS) and Duke-NUHS Medical School has used genomic technologies to better understand intestinal metaplasia (IM), a known risk factor for gastric (stomach) cancer. Patients with IM are six times more likely to develop stomach cancer than those without. This study is an important part of an ambitious investigation to understand why some people develop stomach cancer, while others do not. The research could also help detect patients who are infected with the Helicobacter pylori bacteria, which is also linked to the disease.
READ MORE
|
Promoted by
|
|
|
|
 |
St. Jude Children's Research Hospital via Medical Xpress
St. Jude Children's Research Hospital oncologists have discovered the cell type that gives rise to rhabdomyosarcoma, the most prevalent soft tissue cancer in children. Previously, scientists thought the cancer arose from immature muscle cells, because the tumor resembled muscle under the microscope. However, the St. Jude researchers discovered the cancer arises from immature progenitors that would normally develop into cells lining blood vessels.
READ MORE
The Medical News
A new genetic-based model may explain how a common form of early-stage breast cancer known as ductal carcinoma in situ (DCIS) progresses to a more invasive form of cancer, say researchers at The University of Texas MD Anderson Cancer Center.
The study provides new insight into how DCIS leads to invasive ductal carcinoma (IDC), and provides a clearer understanding of why some of these cancers go undetected. The discovery was made possible by the researchers' development of a new analytical tool called topographic single cell sequencing (TSCS).
READ MORE
| |
PRODUCT SHOWCASE | Advertisement
|
 |
|
Enjoy our journals? There’s an app for those! Journals such as those from the American Cancer Society ™, Journal of Surgical Oncology, Cancer Science and more are now available for your iPad and iPhone. Sample issues and abstracts, as well as open articles, can be accessed for free. A subscription to the journal is required to read the full text. Click here to learn more!
|
|
Cancer Network via Modern Medicine
Lenalidomide plus rituximab failed to demonstrate superiority over standard of care for follicular lymphoma in the randomized, open-label, phase III RELEVANCE trial.
At 120 weeks, neither complete response nor unconfirmed complete response, nor progression-free survival, were superior for lenalidomide plus rituximab compared with standard-of-care rituximab chemotherapy regimens, including R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone), rituximab plus bendamustine, or R-CVP (rituximab plus cyclophosphamide, vincristine and prednisolone).
READ MORE
Healio
The use of a single threshold for determining minimal residual disease risk groups did not account for the response of different genetic subtypes among patients with pediatric acute lymphoblastic leukemia, according to findings published in the Journal of Clinical Oncology. Researchers recommended integrating genetics with minimal residual disease in identifying relapse risk.
READ MORE
 |
|
Novodiax is soon bringing to market 10-minute fast, sensitive and simple Immunoassay (IHC) kits for in vitro diagnostic use to address unmet needs in the intraoperative surgical oncology sector. Learn More
|
|
Wiley via Medical Xpress
A new study reveals that, among patients of advanced age with stage III lung cancer, African Americans and individuals who live in lower income areas are more likely to not receive any treatment. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study also found that patients who receive the standard of care treatment for their cancer live longer.
READ MORE
The Cancer Network via Modern Medicine Network
Among patients with relapsed or refractory multiple myeloma, adding carfilzomib to lenalidomide and dexamethasone (KRd) improves overall survival (OS) compared with lenalidomide and dexamethasone (Rd) alone, especially after first relapse, according to final findings from the randomized phase III ASPIRE trial (abstract 743) presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition last month in Atlanta.
READ MORE
 |
|
Donate now to help Doctors Without Borders bring emergency medical care where it is needed most. Doctors Without Borders USA relies on unrestricted donations from private donors so when an emergency strikes we assess the needs and can act fast. Donate today.
|
|
| ACS CANCER PROGRAMS AND UPDATES |
NCDB
The National Cancer Database (NCDB) is pleased to announce that the Participant User File (PUF) application will open January 22 and be open through February 23, 2018. The NCDB will accept applications for site-specific files, which include cases diagnosed between 2004 and 2015. The NCDB PUF is a Health Insurance Portability and Accountability Act (HIPAA) compliant data file containing cases submitted to the Commission on Cancer's (CoC) NCDB and complies with the terms of the Business Associate Agreement between the American College of Surgeons and cancer programs accredited by the CoC; i.e., no patients or facilities can be identified. The PUF is designed to provide investigators at CoC-accredited cancer programs with a data resource they can use to review and advance the quality of care delivered to cancer patients through analyses of cases reported to the NCDB. For more information review the PUF Website. Questions regarding the NCDB PUFs or the RFA process for a PUF may be directed to NCDB technical staff at NCDB_PUF@facs.org.
READ MORE
NAPBC
The National Accreditation Program for Breast Centers (NAPBC) has released the 2018 NAPBC Standards Manual.
You can download a PDF of the manual by clicking the NAPBC Standards web page.
Click the 2018 NAPBC Standards Manual link at the top of the standards web page. If your browser is set to auto-download, check the downloads folder on your computer after clicking the link.
The 2018 NAPBC Standards Manual will be available online and as a PDF. The NAPBC will not have printed copies of the manual for purchase.
Please contact us at NAPBC@facs.org with any questions or comments.
READ MORE
America College of Surgeons
The latest issue of the American College of Surgeons Selected Readings in General Surgery (SRGS), Surgical Infection, explores the most critical surgical approaches to controlling infection, including surgeon participation in multidisciplinary infection management teams, an enhanced understanding of emerging pathogens and resistant bacteria, timely diagnosis and effective initial therapy.
READ MORE
AJCC
The American Joint Committee on Cancer (AJCC) will be exhibiting at HIMSS18 in Las Vegas, March 5-9, 2018. Make sure to visit Booth 10632 to meet the AJCC staff and learn about the API interface to access the Eighth Edition of the AJCC Cancer Staging Manual.
READ MORE
ACS Quality Programs
The 2018 ACS Quality and Safety Conference: Partners in Quality will be held in Orlando, July 21-24. This education program brings health care professionals together to discuss and apply current knowledge pertaining to national and local quality initiatives in the field of surgery. Attendees will learn techniques to manage, analyze and interpret data to make a positive impact at their facilities.
READ MORE
CoC and NAPBC
Beginning January 1, 2018, both the Commission on Cancer (CoC) and the National Accreditation Program for Breast Centers (NAPBC) introduced new annual accreditation fees.
READ MORE
ACS-CRP
The Commission on Cancer (CoC) initiated a pilot study at 20 CoC accredited facilities in the fall of 2017 as a component of the Comparison of Operative to Monitoring and Endocrine Therapy (COMET) clinical trial (PIs: Drs. Shelley Hwang, Ann Partridge, Alastair Thompson). The study examines the risks and benefits of active surveillance compared to usual care for patients diagnosed with low risk Ductal Carcinoma in situ (DCIS), commonly known as stage 0 breast cancer. The pilot study concluded January 1, 2018. Following data analysis, a CoC Special Study will be launched in spring 2018 to investigate outcomes from DCIS treatment retrospectively.
READ MORE
| IMPORTANT DATES AND DEADLINES |
|
Missed last week's issue? See which articles your colleagues read most.
|
Don't be left behind. Click here to see what else you missed.
|
|
|
|
The Brief
Connect with AJCC
Connect with CoC
Connect with NAPBC
Recent Issues | Subscribe | Unsubscribe | Advertise | Web Version
Colby Horton, Vice President of Publishing, 469-420-2601 | Download media kit
Ashley Harrington, Senior Content Editor, 469-420-2642 | Contribute news
Disclaimer: The Brief is a digest of news selected for the Commission on Cancer (CoC) and the National Accreditation Program for Breast Centers (NAPBC), both quality programs of the American College of Surgeons, from thousands of sources by the editors of MultiBriefs, an independent organization that also manages and sells advertising. The Cancer Programs do not endorse any of the advertised products and services. Opinions expressed in the articles are those of the authors and not of the American College of Surgeons, and the Cancer Programs.
American College of Surgeons
633 N Saint Clair Street | Chicago, IL, 60611-3211 | 800-621-4111 | Contact Us
Learn how to add us to your safe sender list so our emails get to your inbox. |
|
| |
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
